Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-25-002769
Filing Date
2025-01-13
Accepted
2025-01-10 18:56:29
Documents
15
Period of Report
2024-07-12
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0227316-8ka1_abvcbio.htm   iXBRL 8-K/A 27535
2 PRESS RELEASE ea022731601ex99-1_abvcbio.htm EX-99.1 10102
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5654
  Complete submission text file 0001213900-25-002769.txt   223338

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20240712.xsd EX-101.SCH 3003
5 XBRL LABEL FILE abvc-20240712_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abvc-20240712_pre.xml EX-101.PRE 22351
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0227316-8ka1_abvcbio_htm.xml XML 3700
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40700 | Film No.: 25524321
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)